相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。FGF2 antagonizes aberrant TGFβ regulation of tropomyosin: role for posterior capsule opacity
Eri Kubo et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2017)
Prolyl-tRNA synthetase inhibition promotes cell death in SK-MEL-2 cells through GCN2-ATF4 pathway activation
Takeo Arita et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Discovery of a novel prolyl-tRNA synthetase inhibitor and elucidation of its binding mode to the ATP site in complex with L-proline
Ryutaro Adachi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Systemic sclerosis and localized scleroderma-current concepts and novel targets for therapy
Oliver Distler et al.
SEMINARS IN IMMUNOPATHOLOGY (2016)
Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP
John C. McGrath et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients
Lisa M. Rice et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Nitrated fatty acids reverse pulmonary fibrosis by dedifferentiating myofibroblasts and promoting collagen uptake by alveolar macrophages
Aravind T. Reddy et al.
FASEB JOURNAL (2014)
Effects of the immunosuppressant rapamycin on the expression of human α2(I) collagen and matrix metalloproteinase 1 genes in scleroderma dermal fibroblasts
Zenshiro Tamaki et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2014)
Regulation of TGF-β Superfamily Signaling by SMAD Mono-Ubiquitination
Feng Xie et al.
Cells (2014)
A genomic and evolutionary approach reveals non-genetic drug resistance in malaria
Jonathan D. Herman et al.
GENOME BIOLOGY (2014)
ATP-directed capture of bioactive herbal-based medicine on human tRNA synthetase
Huihao Zhou et al.
NATURE (2013)
Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells
Adrian J. Gilbane et al.
ARTHRITIS RESEARCH & THERAPY (2013)
Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase
Tracy L. Keller et al.
NATURE CHEMICAL BIOLOGY (2012)
A Peptide Derived from Endostatin Ameliorates Organ Fibrosis
Yukie Yamaguchi et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Cytokine profiles in localized scleroderma and relationship to clinical features
Katherine Kurzinski et al.
CYTOKINE (2011)
Ablation of Smurf2 reveals an inhibition in TGF-β signalling through multiple mono-ubiquitination of Smad3
Liu-Ya Tang et al.
EMBO JOURNAL (2011)
Guidelines for reporting experiments involving animals: the ARRIVE guidelines
J. C. McGrath et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis
I. Badea et al.
RHEUMATOLOGY (2009)
Basic fibroblast growth factor induces down-regulation of α-smooth muscle actin and reduction of myofibroblast areas in open skin wounds
Shigeki Ishiguro et al.
WOUND REPAIR AND REGENERATION (2009)
Fibroblast growth factor represses Smad-mediated myofibroblast activation in aortic valvular interstitial cells
Melinda C. Cushing et al.
FASEB JOURNAL (2008)
Connective tissue growth factor causes persistent proα2(l) collagen gene expression induced by transforming growth factor-β in a mouse fibrosis model
S Chujo et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2005)
Smad3 as a mediator of the fibrotic response
KC Flanders
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2004)
Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma
A Pines et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2003)
Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism
TL McGaha et al.
ARTHRITIS AND RHEUMATISM (2002)
Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts
TL McGaha et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2002)
分享论文
